Digital Content 
NEWS #PharmaBuzz
10 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/10/3203134/0/en/Roche-s-giredestrant-reduced-risk-of-invasive-disease-recurrence-or-death-by-30-in-ER-positive-early-stage-breast-cancer.html
10 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251210478442/en/Genentechs-Giredestrant-Reduced-Risk-of-Invasive-Disease-Recurrence-or-Death-by-30-in-ER-positive-Early-Stage-Breast-Cancer
18 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251117114377/en/Genentechs-Giredestrant-Becomes-the-First-Oral-SERD-to-Show-Superior-Invasive-Disease-Free-Survival-in-Early-Breast-Cancer
20 Oct 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/the-results-of-the-empress-study-show-the-activity-of-giredestrant-in-reducing-tumor-proliferation-in-erher2--breast-cancer-at-early-stages-without-the-need-for-ovarian-function-suppression-302588871.html
18 Oct 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/esmo-roche-wants-oral-serd-benefit-all-comers-unveils-phase-3-breast-cancer-data
13 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/13/3165275/0/en/Roche-data-at-ESMO-2025-showcase-advances-in-science-and-cancer-care-across-multiple-tumour-types.html
Share 